# Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology

> **NCT02158169** · — · COMPLETED · sponsor: **Hospira, now a wholly owned subsidiary of Pfizer** · enrollment: 2167 (actual)

## Conditions studied

- Chemotherapy-induced Anemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02158169
- **Lead sponsor:** Hospira, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 2167 (ACTUAL)
- **Last updated:** 2015-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02158169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02158169, "Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02158169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*